# Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

> **NCT03219476** · PHASE2 · COMPLETED · sponsor: **Medical College of Wisconsin** · enrollment: 37 (actual)

## Conditions studied

- Breast Cancer
- Invasive Breast Cancer

## Interventions

- **DRUG:** Anastrozole
- **DRUG:** Letrozole
- **DRUG:** Exemestane
- **DRUG:** Tamoxifen

## Key facts

- **NCT ID:** NCT03219476
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-05
- **Primary completion:** 2020-02-04
- **Final completion:** 2025-03-20
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03219476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03219476, "Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03219476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*